Stevanato Group has unveiled the Vertiva on-body delivery system (OBDS) for a range of injectable therapies and large delivery volumes of up to 10mL.

Suitable for a variety of subcutaneous therapies, the Vertiva OBDS is designed to allow the switching between basal and bolus injections, said the Italy-based drug containment and delivery solutions provider.

Vertiva’s design features a single-use pod with a pre-loaded and filled 3mL ISO cartridge and a multi-use controller to provide price and sustainability benefits. Both parts communicate via a patented magnetically connected drive mechanism.

According to the Italian firm, the OBDS allows for the administration of biologics and small-molecule medications by adjusting to various delivery profiles.

Currently, the design of Vertiva is being upgraded to accommodate a wide range of quantities up to 10mL.

The Vertiva device’s preloaded cartridge is sealed within the pod during factory assembly, giving patients a simplified treatment initiation. Vertiva’s connectivity features with digital health applications can also enable home administrations.

After treatment, the controller can be reused and the pod can be more easily detached, thereby minimising the negative effects of electronic components on the environment, the drug delivery solutions provider said.

The OBD system is made to be completely programmable and capable of delivering full-content bolus injections and micro-precision basal dosages for a variety of therapeutic applications, including cardiovascular and metabolic disorders, cancer, immunology, and others.

In addition, the Vertiva platform allows customisations like primary packaging format for larger injection volumes, delivery duration, and user interface.

Stevanato Group drug delivery systems VP Steven Kaufman said: “The Vertiva on-body delivery system supports pharma companies in increasing the accessibility of in-home care and administered treatment options, which can ultimately lead to an improved patient experience.

“We are excited to be offering this device to the market, as it contributes to further strengthening our integrated capabilities in the drug delivery space. By utilizing a re-usable controller, we work towards greater sustainability and see cost benefits to our customers that use Vertiva.”

The Italian firm will use its recently announced partnership with Thermo Fisher Scientific to launch Vertiva in the market. It will be offered as an integrated device and fill-and-finish solution to simplify the management of the pharmaceutical supply chain.